The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 07, 2020
Filed:
Nov. 26, 2019
Bostongene Corporation, Waltham, MA (US);
Feliks Frenkel, Moscow, RU;
Nikita Kotlov, Moscow, RU;
Alexander Bagaev, Moscow, RU;
Maksym Artomov, Kirkwood, MO (US);
Ravshan Ataullakhanov, Moscow, RU;
BostonGene Corporation, Waltham, MA (US);
Abstract
Techniques for determining whether a subject is likely to respond to an immune checkpoint blockade therapy. The techniques include obtaining expression data for the subject, using the expression data to determine subject expression levels for at least three genes selected from the set of predictor genes consisting of BRAF, ACVR1B, MPRIP, PRKAG1, STX2, AGPAT3, FYN, CMIP, ROBO4, RAB40C, HAUS8, SNAP23, SNX6, ACVR1B, MPRIP, COPS3, NLRX1, ELAC2, MON1B, ARF3, ARPIN, SPRYD3, FLI1, TIRAP, GSE1, POLR3K, PIGO, MFHAS1, NPIPA1, DPH6, ERLIN2, CES2, LHFP, NAIF1, ALCAM, SYNE1, SPINT1, SMTN, SLCA46A1, SAP25, WISP2, TSTD1, NLRX1, NPIPA1, HIST1H2AC, FUT8, FABP4, ERBB2, TUBA1A, XAGE1E, SERPINF1, RAI14, SIRPA, MT1X, NEK3, TGFB3, USP13, HLA-DRB4, IGF2, and MICAL1; and determining, using the determined expression levels and a statistical model trained using expression data indicating expression levels for a plurality of genes for a plurality of subjects, whether the subject is likely to respond to the immune checkpoint blockade therapy.